DMD

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wang, R. W.
Right arrow Articles by Lu, A. Y. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wang, R. W.
Right arrow Articles by Lu, A. Y. H.

Vol. 27, Issue 2, 167-172, February 1999

Inhibitory Anti-CYP3A4 Peptide Antibody: Mapping of Inhibitory Epitope and Specificity Toward Other CYP3A Isoforms

Regina W. Wang, Deborah J. Newton, Nini Y. Liu, Magang Shou, Tom Rushmore, and Anthony Y. H. Lu

Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey

An antipeptide antibody has been produced that recognizes CYP3A4 and exhibits greater than 90-95% inhibition on CYP3A4-mediated reactions [Wang RW and Lu AYH (1997) Drug Metab Dispos 25:762-767]. The inhibitory epitope of the 21-amino acid peptide, corresponding to residues 253 to 273 of CYP3A4, has been identified to reside in a 7-amino acid sequence (LEDTQKH: residues 261-267 of CYP3A4). This conclusion was based on the reversal of antibody inhibition of testosterone 6beta -hydroxylation when peptides with overlapping sequence in this region were preincubated with the antibody. In immunoblotting analysis, this antibody did not recognize CYP3A5 or CYP3A7 in microsomes prepared from baculovirus-infected cells containing these two expressed isoforms. In addition, the antipeptide antibody did not inhibit testosterone 6beta -hydroxylation or midazolam 1'- and 4-hydroxylation in microsomes containing expressed CYP3A5 and CYP3A7. Because the corresponding sequence in CYP3A5 (LNDKQKH) and CYP3A7 (LKETQKH) differs from CYP3A4 by only two amino acids, six peptides with either one or two amino acid changes were used to determine which amino acid is essential for antibody-antigen interaction. Our data indicate that Glu, Asp, and Thr in the 7-amino acid sequence of CYP3A4 are critical determinants of selectivity among CYP3A isoforms.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
D. A. Rock, R. S. Foti, and J. T. Pearson
The Combination of Chemical and Antibody Inhibitors for Superior P450 3A Inhibition in Reaction Phenotyping Studies
Drug Metab. Dispos., December 1, 2008; 36(12): 2410 - 2413.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Schulz-Utermoehl, R. J. Mountfield, R. P. Bywater, K. Madsen, P. N. Jørgensen, and K. T. Hansen
Structure-Function Analysis of Human CYP3A4 Using a Specific Proinhibitory Antipeptide Antibody
Drug Metab. Dispos., July 1, 2000; 28(7): 718 - 725.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
T. Schulz-Utermoehl, R. J. Edwards, and A. R. Boobis
Affinity and Potency of Proinhibitory Antipeptide Antibodies Against CYP2D6 Is Enhanced using Cyclic Peptides as Immunogens
Drug Metab. Dispos., May 1, 2000; 28(5): 544 - 551.
[Abstract] [Full Text]

Home page
 Drug Metab. Dispos.Home page
R. W. Wang, D. J. Newton, N. Liu, W. M. Atkins, and A. Y. H. Lu
Human Cytochrome P-450 3A4: In Vitro Drug-Drug Interaction Patterns Are Substrate-Dependent
Drug Metab. Dispos., March 1, 2000; 28(3): 360 - 366.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
Q. Mei, C. Tang, C. Assang, Y. Lin, D. Slaughter, A. D. Rodrigues, T. A. Baillie, T. H. Rushmore, and M. Shou
Role of a Potent Inhibitory Monoclonal Antibody to Cytochrome P-450 3A4 in Assessment of Human Drug Metabolism
J. Pharmacol. Exp. Ther., November 1, 1999; 291(2): 749 - 759.
[Abstract] [Full Text]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics.